Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administ⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$5.23
Price+3.21%
$0.16
$314.206m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$244.530k
-
1y CAGR-
3y CAGR-
5y CAGR-$50.619m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.85
-
1y CAGR-
3y CAGR-
5y CAGR$55.288m
$84.963m
Assets$29.675m
Liabilities$15.556m
Debt18.3%
-0.3x
Debt to EBITDA-$41.037m
-
1y CAGR-
3y CAGR-
5y CAGR